The extrapyramidal neuroleptic syndrome: description and measurement.
D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D004576:Electromyography; D005152:Facial Muscles / Q000503:physiopathology; D005684:Gait / Q000187:drug effects; D006801:Humans; D009069:Movement Disorders / Q000139:chemically induced*; D009129:Muscle Tonus / Q000187:drug effects; D011930:Reaction Time; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014202:Tremor / Q000209:etiology
D014149:Tranquilizing Agents; D002746:Chlorpromazine